Russo Roberto, Capurro Niccolò, Cozzani Emanuele, Parodi Aurora
Department of Health Science (DISSAL), University of Genoa, 16132 Genoa, Italy.
Unit of Dermatology, San Martino Polyclinic Hospital, 16132 Genoa, Italy.
J Clin Med. 2022 Jun 12;11(12):3367. doi: 10.3390/jcm11123367.
Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal bullous disease. At present, the main treatment options are represented by corticosteroids and immunosuppressant drugs. Steroids often need to be administered in high doses, with subsequent adverse events and safety issues, as BP mainly affects elderly people. As dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα has become paramount in the treatment of atopic dermatitis, its use in autoimmune bullous diseases has been theorized and it has been used to treat patients with BP. Dupilumab seems to be an effective and safe option to treat recalcitrant BP. Here, we report the results of a literature review on the use of dupilumab in BP, including a total of 30 treated patients in 9 papers.
大疱性类天疱疮（BP）是最常见的自身免疫性表皮下大疱性疾病。目前，主要的治疗选择以皮质类固醇和免疫抑制药物为代表。由于BP主要影响老年人，类固醇通常需要大剂量给药，随之而来的是不良事件和安全问题。随着度普利尤单抗，一种对人白细胞介素-4受体IL-4Rα具有结合特异性的重组全人IgG4单克隆抗体，在特应性皮炎的治疗中变得至关重要，其在自身免疫性大疱性疾病中的应用已被理论化，并已用于治疗BP患者。度普利尤单抗似乎是治疗顽固性BP的一种有效且安全的选择。在此，我们报告一项关于度普利尤单抗在BP中应用的文献综述结果，包括9篇论文中总共30例接受治疗的患者。
